FEATURED

Colorectal Cancer Immunotherapy, Bystander T Cells

Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.

In Focus: Blinatumomab for Non-Hodgkin Lymphoma

Although blinatumomab shows promising antitumor activity among patients with varying subtypes of NHL, the incidence of neurologic toxicity is high.

TKI Discontinuation Could Save Billions

With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.

Supreme Court Ruling, Arrival of Biosimilars

The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.

Q&A With Filippo Montemurro, MD

Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.

Vaccines Targeting Multiple Myeloma Offer Promise

Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.

Fact Sheet: Dietary Nutrients, Oncogenic HPV

Additional large, well-designed studies are needed to clarify the roles of dietary nutrients in HPV infection persistence and cancer risk.

Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

ASCO: Future Treatment Modalities in Sarcoma

Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells

Immunotherapy of Advanced Colorectal Cancer By Enlisting Bystander T Cells

Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.

In Focus: Blinatumomab for Non-Hodgkin Lymphoma

In Focus: Blinatumomab for Non-Hodgkin Lymphoma

Although blinatumomab shows promising antitumor activity among patients with varying subtypes of NHL, the incidence of neurologic toxicity is high.

TKI Discontinuation for Patients With CML Could Save Billions

TKI Discontinuation for Patients With CML Could Save Billions

With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.

Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain

Supreme Court Ruling Should Hasten Arrival of Biosimilars, But Uncertainties Remain

The Supreme Court's ruling in the Amgen v Sandoz case may hasten the arrival of lower-cost biosimilar versions of biologics in the clinic, potentially saving billions of dollars in health care spending.

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters